Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $9.75

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $9.75.

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, January 21st.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $3.87 on Friday. Aclaris Therapeutics has a 1 year low of $1.05 and a 1 year high of $4.89. The stock has a market capitalization of $419.31 million, a price-to-earnings ratio of -2.80 and a beta of 0.41. The company’s 50 day simple moving average is $3.05 and its 200 day simple moving average is $2.32.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%.The firm had revenue of $3.30 million for the quarter, compared to the consensus estimate of $1.59 million. As a group, analysts anticipate that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ACRS. Three Bridge Wealth Advisors LLC acquired a new stake in shares of Aclaris Therapeutics during the third quarter valued at about $1,358,000. Acadian Asset Management LLC raised its holdings in Aclaris Therapeutics by 10.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,433,850 shares of the biotechnology company’s stock valued at $3,453,000 after buying an additional 238,659 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Aclaris Therapeutics in the 2nd quarter valued at approximately $28,000. ProShare Advisors LLC acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $26,000. Finally, BNP Paribas Financial Markets grew its holdings in Aclaris Therapeutics by 59.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 9,894 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.